AstraZeneca's Lung Cancer Drug Misses Phase 3 Survival Goal

02:26 AM EST, 12/22/2025 (MT Newswires) -- British drugmaker AstraZeneca (AZN.L, AZN.ST) said Monday that a late-stage study of ceralasertib in combination with Imfinzi failed to meet its primary endpoint of overall survival in patients with locally advanced or metastatic non-small cell lung cancer. The phase 3 Latify trial enrolled 594 patients whose disease had progressed on or after prior anti-PD-(L)1 therapy and platinum-based chemotherapy. Participants received oral ceralasertib at 240 milligrams twice daily for seven days, alongside a fixed 1,500-milligram dose of Imfinzi. AstraZeneca said the combination therapy was generally well tolerated, with a safety profile consistent with the known profiles of each medicine.